Latex Agglutination Test Kits Market Forecasts to 2028 - Global Analysis By Test Type, By Sample Type (Urine, Blood, Cerebrospinal Fluid, Sperm and Other Sample Types), By Indication, By Product, By Application, By End User and By Geography

According to Stratistics MRC, the Global Latex Agglutination Test Kits Market is accounted for $475.4 million in 2022 and is expected to reach $685.9 million by 2028 growing at a CAGR of 6.3% during the forecast period. The identification of antibodies or antigens in body fluids such as cerebrospinal fluid (CSF), blood, urine, and saliva is usually done using latex agglutination test kits. The test kits include coating either an antigen or an antibody on a latex bead-based artificial carrier particle. The increasing prevalence of autoimmune and infectious disorders as well as the wide range of applications for these kits help to drive adoption of the product.

According to the National Institutes of Health (NIH) in 2021, the global incidence of meningitis is estimated to be 20.0 cases per 100,000 people, representing about 1.2 million cases.

Market Dynamics:

Driver:

Diverse application areas of latex agglutination test kits

Hepatitis, meningitis, rheumatoid arthritis, tonsillitis, and other streptococcal diseases are frequently diagnosed with latex agglutination test kits. The use of these kits to diagnose a variety of viral and autoimmune diseases leads to a bright future for this sector. The Wellcogen Strep B Rapid Latex Agglutination Test, the Wellcogen Strep B 30 Pk for Staphylococcus, the Waaler Rose Latex Kits for rheumatoid arthritis, the E. coli O157 Latex Test for E. coli, and the ASI Rubella test for Rubella Virus are a few instances of commercially accessible products.

Restraint:

Emergence of new and reliable alternate diagnostics

Despite the fact that latex agglutination test kits have a number of benefits for diagnostic care, the development of innovative and trustworthy alternative diagnostics, particularly in high-growing markets like the United States and Europe, has significantly hampered market growth. These test kits are very rapid, simple, and affordable. Standardization is also required to prevent artificially positive results. The market is anticipated to have limited growth possibilities due to the limitations of these kits and higher technological advancements in infectious diseases diagnostics.

Opportunity:

Rising prevalence of infectious and autoimmune diseases

For common infectious diseases such as meningitis, pneumonia, hepatitis, Haemophilus influenzae, typhoid, and tuberculosis, latex agglutination kits are provided. Since these test kits offer quick diagnosis, the increasing prevalence of certain infectious diseases will drive demand for products. Additionally, the rise in autoimmune disorders like lupus and rheumatoid arthritis cases, as well as the accessibility of these kits in developing countries, encourage the rapid uptake of the products.

Threat:

Human error in interpretation of results

Because immunoagglutination assays do not have an endpoint, reaction time analysis must be taken into consideration while designing an experiment. Also, as the reaction time increases, the liquid dries and the particles settle, making it more difficult to read the results and increasing the likelihood of false-positive interpretations. This assay can only be classified as a strong, intermediate, or weak positive by trained specialists working in the field. In addition, compared to LAT, other more sophisticated tests, including enzyme-linked immunosorbent assays and chemiluminescence immunoassays, give results that are more accurate and rapid.

Covid-19 Impact:

Due to an increase in specific tests (C-reactive protein (CRP) and D-dimer) performed during the COVID-19 pandemic, the pandemic had a favorable effect. As patient visits to healthcare institutions decreased, fewer diagnoses of other diseases, including E. coli, pneumonia, and autoimmune disease, occurred. This had a detrimental influence on the market. Due to supply chain disruptions during the COVID-19 pandemic, the situation for businesses that manufacture latex agglutination test kits was unpredictable. The decrease was seen as a result of a number of factors, including a decrease in the number of autoimmune, E. coli, and pneumonia tests performed, a decrease in overall patient visits to hospitals and diagnoses, a reduction in the ability of hospitals to diagnose diseases other than COVID-19, and others.

The antigen testing segment is expected to be the largest during the forecast period

Due to the enormous number of patients affected by diverse bacterial, viral, and fungal infections, the antigen testing segment held the largest share of the global market for latex agglutination test kits. Antigen testing is recommended for the majority of these infectious disease patients in order to diagnose the illness. In 2020, a study was carried out at the Children's Hospital of Zhejiang University, School of Medicine, according to the Journal of Clinical Laboratory Analysis (Hangzhou, China). It was discovered that this test had favorable outcomes and was effective in detecting rotavirus and adenovirus antigens. This test had a rotavirus detection sensitivity of 81.0% and a specificity of 97.4%.

The blood segment is expected to have the highest CAGR during the forecast period

Because of its widespread use in test kits for antigen and antibody latex agglutination, the blood segment is anticipated to have lucrative expansion throughout the forecast period. Blood or serum samples are required for a number of bacterial and fungal detections. These elements boosted the segment's growth. For instance, a retrospective analysis of patients with cryptococcosis from 2002 to 2019 at Barnes-Jewish Hospital indicated that the sensitivity for serum CrAg latex agglutination was assessed to be 94.7%, according to a report by the National Institutes of Health (NIH) in 2020.

Region with largest share:

Due to the wide range of diseases for which these kits are used, as well as the presence of significant market participants in North America, it is predicted that the region would dominate the global market during the projection period. Moreover, the broad use of these test kits and the rising number of labs with Clinical Laboratory Improvement Amendments (CLIA) certification are anticipated to fuel market expansion in the region.

Region with highest CAGR:

Owing to the region's significant share of the worldwide burden of infectious diseases, Asia-Pacific is predicted to experience the highest CAGR during the forecast period. Moreover, the promotion of latex agglutination testing will be aided by the growth of hospital-based laboratories and independent laboratories. Furthermore, increasing R&D initiatives to evaluate the effectiveness of these kits and rising government spending on patient diagnostic care are other factors driving market expansion in this region.

Key Players in the market

Some of the key players in Latex Agglutination Test Kits market include Arlington Scientific, Inc., Atlas Medical GmbH, BioLegend, Bio-Rad Laboratories, Inc., Biotec (Novacyt), Creative Diagnostics, Hardy Diagnostics, HiMedia Laboratories, Liofilchem S.r.l., Pro Lab Diagnostics Inc. and Thermo Fisher Scientific Inc..

Key Developments:

In July 2022, Bio-Rad Laboratories, Inc. launched two products, the Synthetic Negative Run Control for tick-borne, meningitis/encephalitis, and sexually-transmitted infections products, and HAI Negative Run Control for hospital-associated infections products.

In June 2022, Thermo Fisher Scientific partnered with Diagnostic BioSystems (DBS) to offer a wide spectrum of primary antibodies in the U.S.

In April 2022, Bio-Rad Laboratories, Inc. participated in the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2022. The company showcased its complete range of infectious disease testing systems, reagents, and quality controls for optimizing testing workflows.

In October 2021, Hardy Diagnostics launched the HardyCHROM Candida + Auris. It is a chromogenic media for the selective isolation and differential identification of Candida species.

In August 2021, Hardy Diagnostics launched the HardyCHROM Group A Strep agar. It is a chromogenic medium for the selective cultivation and differentiation of Group A Streptococcus (S. pyogenes) from clinical specimens.

Test Types Covered:

• Antibody Detection
• Antigen Testing
• Other Test Types

Sample Types Covered:

• Urine
• Blood
• Cerebrospinal Fluid (Lumber Puncture)
• Sperm
• Other Sample Types

Indications Covered:

• Bacterial Meningitis
• C Reactive Protein (CRP)
• Rheumatoid Arthritis (RA)
• Staphylococcus Aureus
• E.coli
• Other Indications

Products Covered:

• Hemagglutination Inhibition
• Indirect Fuorescent Antibody Test
• Serum Neutralization
• Other Products

Applications Covered:

• Research Use
• Diagnostics
• Specialty Clinics
• Other Applications

End Users Covered:

• Standalone Clinical Laboratories
• Hospital-based Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances